Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 14/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.61 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.50 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20086726 | 0.94 | PTGFR (0.77) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL25218705 | 0.92 | PTGFR (0.76) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| Bromide SCHEMBL2590529 | 0.92 | PTGFR (0.75) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL16037398 | 0.91 | PTGFR (0.86) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL16037401 | 0.91 | PTGFR (0.86) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL18558637 | 0.91 | PTGFR (0.86) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL25329574 | 0.91 | PTGFR (0.86) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL13260245 | 0.91 | PTGFR (0.86) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL16037840 | 0.91 | PTGFR (0.86) | PTGFRABCC4ABCB11PTGER3TBXA2R | |
| SCHEMBL16037841 | 0.91 | PTGFR (0.86) | PTGFRABCC4ABCB11PTGER3TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10869874-B2 | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat | TOPOKINE THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200282059-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT | TOPOKINE THERAPEUTICS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-10556012-B2 | Compositions and methods for topical delivery of prostaglandins to subcutaneous fat | TOPOKINE THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10335418-B2 | Methods and compositions for treating metabolic syndrome | TOPOKINE THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180200372-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT | TOPOKINE THERAPEUTICS, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180169111-A1 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT | TOPOKINE THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9820993-B2 | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat | TOPOKINE THERAPEUTICS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170136032-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME | TOPOKINE THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9089579-B2 | Methods and compositions for treating metabolic syndrome | TOPOKINE THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140045933-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME | TERAKINE THERAPEUTICS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8519178-B2 | Method for the purification of prostaglandins | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2013-08-27 | — | — | US | disclosed |
| US-20100324313-A1 | METHOD FOR THE PURIFICATION OF PROSTAGLANDINS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7268239-B2 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2007-09-11 | — | — | US | disclosed |
| US-7268239-B2 | Process for the preparation of prostaglandins and analogues thereof | RESOLUTION CHEMICALS LIMITED (GB) | 2007-09-11 | — | — | US | disclosed |
| US-7161042-B2 | Protected diols for prostaglandin synthesis | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7161042-B2 | Protected diols for prostaglandin synthesis | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200372-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT | FFAR1, FFAR4, FFAR2 | PTGFR 10/4885ABCC4 2669/4885ABCB11 2123/4885 |
| US-20180169111-A1 | METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT | FFAR1, FFAR4, FFAR2 | PTGFR 10/4885ABCC4 1607/4885ABCB11 2449/4885 |
| US-20170136032-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME | SLC5A1, GPR119, SLC5A2 | PTGFR 3935/4885ABCC4 821/4885ABCB11 161/4885 |
| US-10556012-B2 | Compositions and methods for topical delivery of prostaglandins to subcutaneous fat | FFAR1, FFAR4, FFAR2 | PTGFR 10/4885ABCC4 2669/4885ABCB11 2123/4885 |
| US-10335418-B2 | Methods and compositions for treating metabolic syndrome | SLC5A1, GPR119, SLC5A2 | PTGFR 3935/4885ABCC4 821/4885ABCB11 161/4885 |
| US-20100324313-A1 | METHOD FOR THE PURIFICATION OF PROSTAGLANDINS | PTGES, PTGES2, PTGS2 | PTGFR 11/4885ABCC4 3932/4885ABCB11 1579/4885 |
| US-20200282059-A1 | COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FAT | FFAR1, FFAR4, FFAR2 | PTGFR 10/4885ABCC4 2669/4885ABCB11 2123/4885 |
| US-10869874-B2 | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat | FFAR1, FFAR4, FFAR2 | PTGFR 10/4885ABCC4 1607/4885ABCB11 2449/4885 |
| US-20140045933-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME | SLC5A1, GPR119, SLC5A2 | PTGFR 3898/4885ABCC4 849/4885ABCB11 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.